X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs WYETH LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH WYETH LTD PANACEA BIOTECH/
WYETH LTD
 
P/E (TTM) x 170.0 27.7 613.3% View Chart
P/BV x 3.8 5.3 70.6% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 PANACEA BIOTECH   WYETH LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
WYETH LTD
Mar-13
PANACEA BIOTECH/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1491,044 14.2%   
Low Rs82818 10.1%   
Sales per share (Unadj.) Rs84.1298.6 28.2%  
Earnings per share (Unadj.) Rs-18.357.2 -32.0%  
Cash flow per share (Unadj.) Rs-6.758.4 -11.5%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs83.7249.5 33.6%  
Shares outstanding (eoy) m61.2522.72 269.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.1 44.0%   
Avg P/E ratio x-6.316.3 -38.8%  
P/CF ratio (eoy) x-17.215.9 -108.2%  
Price / Book Value ratio x1.43.7 37.0%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m7,07421,157 33.4%   
No. of employees `0002.80.5 558.9%   
Total wages/salary Rs m1,449400 362.3%   
Avg. sales/employee Rs Th1,874.113,787.4 13.6%   
Avg. wages/employee Rs Th527.0813.0 64.8%   
Avg. net profit/employee Rs Th-407.72,643.3 -15.4%   
INCOME DATA
Net Sales Rs m5,1546,783 76.0%  
Other income Rs m100353 28.3%   
Total revenues Rs m5,2547,136 73.6%   
Gross profit Rs m-7661,617 -47.4%  
Depreciation Rs m71127 2,672.9%   
Interest Rs m1,5036 27,327.3%   
Profit before tax Rs m-2,8811,938 -148.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-5 -34,723.5%   
Tax Rs m17632 2.7%   
Profit after tax Rs m-1,1211,301 -86.2%  
Gross profit margin %-14.923.8 -62.4%  
Effective tax rate %-0.632.6 -1.8%   
Net profit margin %-21.819.2 -113.5%  
BALANCE SHEET DATA
Current assets Rs m3,8106,984 54.6%   
Current liabilities Rs m8,3652,056 406.9%   
Net working cap to sales %-88.472.6 -121.7%  
Current ratio x0.53.4 13.4%  
Inventory Days Days15699 156.8%  
Debtors Days Days6724 280.8%  
Net fixed assets Rs m14,480244 5,927.2%   
Share capital Rs m61227 27.0%   
"Free" reserves Rs m9035,441 16.6%   
Net worth Rs m5,1275,668 90.5%   
Long term debt Rs m5,83225 23,326.8%   
Total assets Rs m19,4337,901 246.0%  
Interest coverage x-0.9353.3 -0.3%   
Debt to equity ratio x1.10 25,787.2%  
Sales to assets ratio x0.30.9 30.9%   
Return on assets %2.016.5 11.9%  
Return on equity %-21.922.9 -95.3%  
Return on capital %3.634.0 10.7%  
Exports to sales %24.50.2 11,239.4%   
Imports to sales %10.236.3 28.0%   
Exports (fob) Rs m1,26415 8,539.2%   
Imports (cif) Rs m5252,465 21.3%   
Fx inflow Rs m1,53915 10,126.3%   
Fx outflow Rs m9422,677 35.2%   
Net fx Rs m597-2,662 -22.4%   
CASH FLOW
From Operations Rs m599923 64.9%  
From Investments Rs m-438317 -138.2%  
From Financial Activity Rs m-303-481 62.9%  
Net Cashflow Rs m-141759 -18.6%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.6 11.3 5.3%  
FIIs % 1.3 7.2 18.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 30.4 77.6%  
Shareholders   10,259 21,978 46.7%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 19, 2018 01:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS